登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002940 证券简称：昂利康 公告编号：2025-062 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到证监会指定媒体仔细阅读半年度报告全文。 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 是否以公积金转增股本 □是 √否 公司经本次董事会审议通过的利润分配预案为：以196,108,486股为基数，向全体股东每10股派发现金红 利1.00元（含税），送红股0股（含税），不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 二、公司基本情况 1、公司简介 ■ 2、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ 3、公司股东数量及持股情况 单位：股 ■ 持股5%以上股东、前10名股东及前10名无限售流通股股东参与转融通业务出借股份情况 □适用 √不适用 前10名股东及前10名无限售流通股股东因转融通出借/归还原因导致 ...

公告称，该CD47抗体对CD47靶点的结合活性因偶联了遮罩而大大降低，在血液中高度稳定，从而避免 了CD47抗体活性所导致的血液毒性。临床前研究结果显示，注射用ALK-N002/IMD-1005在SHP77（人 小细胞肺癌）及Raji（淋巴瘤）CDX肿瘤模型中，均能呈剂量依赖性抑制肿瘤生长，药效突出，并在临 床前动物安全性评价实验中显现出优秀的安全性。公司指出，综合考虑药效、药代、安全性数据，计算 药物安全窗能满足临床研究需求，药物即将进入临床申报阶段。 值得一提的是，昂利康与亲合力的合作早有基础，2024年2月双方就另一款肿瘤微环境激活药物ALK- N001/QHL-1618达成授权，目前研发进程已顺利推进至Ⅰ期临床试验阶段。截至公告日，就ALK-N001 药物，昂利康已累计向亲和力支付4888万元。此次加码ALK-N002，不仅延续了技术平台协同优势，更 通过引入新机制药物强化公司在创新药领域的研发厚度与市场竞争力，是昂利康实践"仿创协同"战略转 型的关键落子。 3.89亿元投资扩产，筑牢头孢酶法工艺领头地位 8月27日晚，昂利康（002940.SZ）披露半年度报告。2025年上半年实现营业收入7.24亿 ...

转自：证券时报 人民财讯8月27日电，昂利康(002940)8月27日晚间公告，公司拟以自有资金及银行贷款在浙江省嵊州市 投资建设"年产8000吨阿莫西林、2000吨氨苄西林建设项目"，项目计划投资金额为3.89亿元。通过自建 原料药产能，公司将进一步完善在抗感染领域的产品布局，强化上游原料供应稳定性，提升产业链协同 效率，有效增强成本控制和市场竞争力，为可持续发展奠定坚实基础。 ...

Core Insights - The report maintains a positive outlook on the pharmaceutical and biotechnology sector, with a focus on raw material prices as of July 2025 [1][3] Hormonal Drug Price Situation - In July 2025, prices for hormonal drugs such as progesterone, medroxyprogesterone acetate, saponin, dexamethasone sodium phosphate, hydrocortisone, and acetate hydrocortisone remained stable month-on-month. Year-on-year, progesterone prices remained unchanged, while medroxyprogesterone acetate, saponin, dexamethasone sodium phosphate, hydrocortisone, acetate hydrocortisone, and saponin saw declines of 1.85%, 3.23%, 84.22%, 14.04%, 12.15%, and 5.66% respectively [6][10] Antibiotic Intermediate Price Situation - In July 2025, prices for antibiotic intermediates such as 4-AA remained stable month-on-month, while 7-ADCA, 7-ACA, 6-APA, and penicillin industrial salt saw decreases of 1.92%, 2.08%, 8.33%, and 7.89% respectively. Year-on-year, 7-ADCA, 7-ACA, 6-APA, 4-AA, and penicillin industrial salt prices fell by 1.92%, 4.08%, 45.00%, 13.92%, and 41.67% respectively [10][11] β-Lactam Antibiotic Price Situation - In July 2025, prices for β-lactam antibiotics such as cephalexin, ampicillin, cefotaxime sodium, and cefaclor remained stable month-on-month. However, ceftriaxone sodium, cefixime, and amoxicillin saw declines of 1.55%, 1.37%, and 11.36% respectively. Year-on-year, cephalexin, ampicillin, ceftriaxone sodium, cefotaxime sodium, cefixime, and amoxicillin prices decreased by 1.82%, 2.22%, 9.29%, 3.40%, 12.20%, and 35.00% respectively, while cefaclor saw an increase of 6.12% [15][17] Cardiovascular Drug Price Situation - In July 2025, prices for cardiovascular raw materials such as valsartan, irbesartan, telmisartan, lisinopril, enalapril maleate, and atorvastatin calcium remained stable month-on-month. Year-on-year, valsartan prices decreased by 1.54%, while the other drugs remained unchanged [19][20]

Investment Chain - Prices of copper, aluminum, lead, tin, and silver have risen since June 2025. Fixed asset investment growth rate has decreased to 3.70% as of May 2025, with real estate development investment declining by 10.70% and manufacturing fixed asset investment down to 8.50% [1][2] - Infrastructure investment growth rate has also decreased to 10.42%. Since June 2025, prices of gold, zinc, and nickel have fallen, while coal prices slightly decreased to 663 RMB/ton [1][2] Consumption Chain - Retail sales growth rate has increased, with nominal growth rebounding to 6.40% in May 2025 and cumulative growth rising to 5.00%. Automobile sales growth rate for May 2025 increased to 11.15% [2][3] - The cumulative growth rate for commercial housing sales has declined to -3.62%. Retail sales of home appliances surged with a growth rate of 56.98% in May 2025 [2][3] Export Chain - Export growth rates to the US, Japan, and ASEAN have decreased, while exports to the EU have increased. In May 2025, the export growth rate for toys, lighting, coke, coal, steel, ships, plastics, and auto parts rose, while agricultural products, furniture, and refined oil exports saw declines [3][4] - The electronic export growth rate increased to 21.17% in May 2025, while textile and clothing exports fell to 1.98% [3][4] Price Chain - Oil prices rose, with WTI reaching 64.37 USD/barrel on June 24, 2025. Prices for PVC and MDI have decreased, with PVC at 4680 RMB/ton and pure MDI at 17100 RMB/ton as of June 20, 2025 [4] - Pork prices dropped to 14.45 RMB/kg on June 11, 2025, while new credit increased to 620 billion RMB in May 2025 [4]

Investment Chain - Since June, prices of copper, aluminum, lead, tin, and silver have increased. In May 2025, the cumulative year-on-year growth rate of fixed asset investment decreased to 3.70%, while the decline in real estate development investment narrowed to -10.70%. The cumulative year-on-year growth rate of manufacturing fixed asset investment fell to 8.50%, and infrastructure investment decreased to 10.42% [4][8] - In June 2025, prices of copper, aluminum, lead, tin, and silver have risen, while prices of gold, zinc, and nickel have decreased. The price of thermal coal slightly decreased to 663 RMB/ton, and the price of coking coal also slightly declined. The average price of ordinary cement saw a minor decrease, while steel prices have risen [4][8] Consumption Chain - The cumulative year-on-year growth rate of social consumption has increased, with automobile sales showing a year-on-year growth rate of 11.15% in May 2025. The nominal year-on-year growth rate for May 2025 rebounded to 6.40%, and the cumulative nominal year-on-year growth rate rose to 5.00% [4][9] - The cumulative year-on-year growth rate of commercial housing sales area saw a larger decline, dropping to -3.62%. The retail sales of home appliances in May 2025 increased significantly, with a year-on-year growth rate of 56.98% [4][9] Export Chain - In May 2025, the year-on-year growth rate of export amounts to the United States, Japan, and ASEAN decreased, while the growth rate of exports to the European Union increased. The cumulative year-on-year growth rate of exports for toys, lamps, coke, coal, steel, ships, plastics, and auto parts rose, while the growth rates for agricultural products, furniture, refined oil, crude oil, and aluminum decreased [4][10] - The OECD leading indicator for the United States fell to 100.26 in May 2025. The electronic export amount's year-on-year growth rate increased to 21.17%, while the textile and clothing export amount's growth rate decreased to 1.98% [4][10] Price Chain - Oil prices have risen, with WTI reaching 64.37 USD/barrel on June 24, 2025. The price of PVC dropped to 4680 RMB/ton, and the prices of pure MDI and polymer MDI decreased to 17100 RMB/ton and 16200 RMB/ton, respectively [4][11] - The price of pork decreased to 14.45 RMB/kg on June 11, 2025, while cotton prices increased and sugar prices decreased. The increase in new credit in May 2025 reached 620 billion RMB, and the year-on-year growth rate of life insurance premium income rose to 1.15% [4][11]

Group 1: Rare Earth Market Dynamics - China holds a dominant position in the global rare earth market, accounting for approximately 70% of mining, 85% of refining capacity, and 90% of production of rare earth metal alloys and magnets [1][3] - Despite the U.S. having significant rare earth reserves, its industry has lagged due to minimal investment over the past decades, leading to heavy reliance on imports from China [1][3] - U.S. companies have announced ambitious plans to break China's monopoly within a year, but experts suggest that restructuring the entire supply chain could take at least a decade [3] Group 2: U.S. Pharmaceutical Dependency - Over 60% of everyday medications and raw materials in the U.S. depend on Chinese supplies, with 80% of the raw materials for basic drugs like amoxicillin sourced from China [3] - The push for manufacturing to return to the U.S. may lead pharmaceutical companies to abandon the domestic market due to cost pressures, potentially resulting in a severe shortage of medications [3] Group 3: China-Kazakhstan Cooperation - China has made significant strides in international cooperation, exemplified by signing over 10 bilateral agreements with Kazakhstan, including a notable nuclear power project valued at over $10 billion [4][5] - The partnership with Kazakhstan allows China to secure stable uranium supplies and enhances its influence in the global nuclear energy sector [7][9] - The cooperation model between China and Kazakhstan is seen as a win-win, providing advanced technology and financial support to Kazakhstan while expanding China's global manufacturing footprint [9] Group 4: U.S.-China Geopolitical Competition - The competition between the U.S. and China in critical sectors has evolved beyond trade, representing a clash of development models [9] - U.S. attempts to reshape supply chains through political means have not addressed fundamental issues and may lead to deeper challenges in various sectors [9] - China's approach of promoting international cooperation through the Belt and Road Initiative is positioning it as a leader in global development trends [9]

Group 1: Rare Earth Industry - The U.S. is attempting to challenge China's dominance in the rare earth market, claiming it can break China's monopoly within a year, despite China's control over 70% of global rare earth mining and 85% of refining capacity [1] - U.S. companies lack the mature separation and purification technology that China has developed over 30 years, making the claim of a quick turnaround unrealistic [1] - The U.S. Department of Energy's funding for 15 rare earth projects has not resulted in any commercial production, highlighting the challenges faced by U.S. firms in achieving independence from Chinese technology [1] Group 2: Pharmaceutical Industry - Over 60% of daily-use medications and raw materials in the U.S. come from China, with 80% of basic drug raw materials like amoxicillin relying on Chinese supply [3] - The potential consequences of aggressive manufacturing repatriation policies could lead to a situation where U.S. pharmaceutical companies abandon the domestic market, resulting in a "no medicine available" scenario [3] Group 3: Nuclear Energy Sector - China has secured a significant nuclear power project in Kazakhstan, with the China National Nuclear Corporation becoming a strategic partner for Kazakhstan's nuclear energy development, valued at over $10 billion [3][5] - The comprehensive "full industry chain solution" provided by China, including financing and waste management, addresses Kazakhstan's needs more effectively than competitors [5] - The strategic partnership with Kazakhstan not only ensures uranium supply for China's new energy sector but also opens international markets for Chinese nuclear technology [5] Group 4: Broader Strategic Implications - The competition between the U.S. and China extends beyond trade deficits to a clash of development models, with China promoting a narrative of building a community with a shared future [7] - While the U.S. focuses on tariffs and political maneuvers, China is leveraging technology and capital to secure high-end manufacturing contracts and redefine globalization [5][7]

Group 1 - China has quietly tightened the approval process for rare earth exports, leading to production halts in multiple automotive production lines in Europe and signaling distress from the U.S. pharmaceutical industry [1][5] - China controls over 92% of the global refined rare earth production, and 80% of the raw materials for amoxicillin sold in the U.S. come from China, indicating a significant dependency on Chinese exports [1][5] - The tightening of rare earth export approvals has created waves in the high-tech manufacturing sector in Europe and the U.S., as rare earths are essential for national development and technological advancement [3][4] Group 2 - The U.S. pharmaceutical supply chain is heavily reliant on China, with experts warning that any restrictions from China could lead to a critical shortage of medications in the U.S. [5][8] - Historical context shows that the U.S. has been aware of its dependency on Chinese imports, with previous administrations attempting to investigate and address the vulnerabilities in the pharmaceutical sector [7][8] - Rebuilding the U.S. pharmaceutical supply chain is projected to take at least five years, highlighting the complexity and time required to establish domestic production capabilities [7][8] Group 3 - The U.S. is also aware of China's leverage in other critical sectors, including rare metals, photovoltaic components, batteries, and new materials, which could further impact the U.S. economy if restrictions are imposed [10] - As China's overall strength continues to grow, it is recognized as a key player in the global supply chain, with potential disruptions having far-reaching consequences for the international market [10]

Core Viewpoint - The article highlights the significant leverage China holds over the U.S. in various critical industries, particularly in rare earth elements, pharmaceuticals, battery materials, and solar energy, raising concerns about U.S. dependency and national security [1][10][44]. Group 1: Rare Earth Elements - China controls 92% of the world's refined rare earth elements, while the U.S. relies on China for 70% of its rare earth compounds and metals from 2020 to 2023 [6][10]. - The U.S. Department of Defense has invested $439 million since 2020 to establish rare earth processing facilities, but production is not expected to begin until 2027, with capacity far below that of China [7][10]. Group 2: Pharmaceuticals - The U.S. pharmaceutical supply chain is heavily reliant on China, with 80% of the raw materials for common drugs like amoxicillin sourced from China [12][13]. - Over 90% of imported hydrocodone and ibuprofen in the U.S. comes from China, indicating a critical dependency on Chinese raw materials for essential medications [15]. Group 3: Battery Materials - China produces over 70% of the world's lithium batteries and controls more than 80% of the global market for battery components [17]. - Chinese companies control 8 out of 14 major cobalt mines in the Democratic Republic of Congo, accounting for over half of the country's cobalt production, with the U.S. relying on China for 70% of its cobalt compound imports [19]. Group 4: Solar Energy - China dominates the solar energy supply chain, with an 80% share in global production across all segments [21]. - In 2023, China accounted for over 80% of the global market for solar products, making it essential for any country aiming to develop clean energy [23]. Group 5: U.S. Response and Challenges - The U.S. has attempted to address its dependency by investigating the pharmaceutical supply chain and considering tariffs, but achieving supply chain localization could take 5 to 10 years [26][28]. - Challenges include potential supply shortages, increased production costs, and significant technological gaps that hinder the U.S. from catching up with China's capabilities [30][34].